What is the global market size of Narcolepsy Drugs Market?

Global Narcolepsy Drugs Market size was valued at USD 2680.06 million in 2021 and is poised to grow from USD 2937.35 million in 2022 to USD 6115.61 million by 2030, growing at a CAGR of 9.6% in the forecast period (2023-2030).

What is the key market trend for Global Narcolepsy Drugs Market?

The market growth driver for the narcolepsy market is the increasing prevalence of narcolepsy among various population segments worldwide. An increase in the number of persons experiencing various sleep disorders and hallucinations would have a positive impact on the global market for narcolepsy drugs. Additionally, the rise in obesity rates worldwide are anticipated to support future growth in the global narcolepsy market. In the coming years, it is anticipated that government initiatives and steps to raise awareness of narcolepsy would increase demand for narcolepsy products. The end-use category for hospitals is anticipated to contribute the most to the overall market because of the rise in narcolepsy patients seeking treatment at these facilities.

Narcolepsy Drugs Companies

Narcolepsy Drugs Market Competitive Landscape

Narcolepsy Drugs Market Top Player's Company Profiles

Jazz Pharmaceuticals
Teva Pharmaceutical Industries
Novartis
Mylan N.V.
Shire Pharmaceuticals (acquired by Takeda Pharmaceutical Company Limited)
Ligand Pharmaceuticals
Bioprojet SCR
Arena Pharmaceuticals
Avadel Pharmaceuticals
Graymark Healthcare
Balance Pharmaceuticals
Theravance Biopharma
Biocodex
Flamel Technologies
Otsuka Pharmaceutical
Biogen
Aurobindo Pharma
Glenmark Pharmaceuticals
Lupin Pharmaceuticals

Narcolepsy Drugs Market

FAQs

Narcolepsy Drugs Market is expected to rise from USD 3.21 billion in 2022 and rise from USD 3.52 billion in 2023 to reach USD 7.32 billion by 2031, by rising at a CAGR of 9.60% during the forecast period (2024- 2031).

The competitive landscape of the narcolepsy treatment market gives information by competitor. Company overview, financials, revenue generated, market potential, investments in R&D, new market initiatives, presence, production facilities, company strengths and weaknesses, product launch, clinical trial pipelines, product approvals, patents, product width and breadth, application dominance, and technology lifeline curve are among the details provided. The aforementioned data points are limited to the companies' market research focus on narcolepsy treatment. 'Jazz Pharmaceuticals', 'Teva Pharmaceutical Industries', 'Novartis', 'Mylan N.V.', 'Shire Pharmaceuticals (acquired by Takeda Pharmaceutical Company Limited)', 'Ligand Pharmaceuticals', 'Bioprojet SCR', 'Arena Pharmaceuticals', 'Avadel Pharmaceuticals', 'Graymark Healthcare', 'Balance Pharmaceuticals', 'Theravance Biopharma', 'Biocodex', 'Flamel Technologies', 'Otsuka Pharmaceutical', 'Biogen', 'Aurobindo Pharma', 'Glenmark Pharmaceuticals', 'Lupin Pharmaceuticals'

Growing awareness of narcolepsy treatment is a significant driver propelling the narcolepsy market from 2023 to 2030. Additionally, since modafinil has fewer adverse effects than other stimulants, using it to treat patients is boosting the demand for it. Therefore, the adoption of suitable therapy can aid in the prevention of such diseases, propelling the narcolepsy market from 2022 to 2026.

The market growth driver for the narcolepsy market is the increasing prevalence of narcolepsy among various population segments worldwide. An increase in the number of persons experiencing various sleep disorders and hallucinations would have a positive impact on the market for narcolepsy drugs. Additionally, the rise in obesity rates worldwide are anticipated to support future growth in the narcolepsy market. In the coming years, it is anticipated that government initiatives and steps to raise awareness of narcolepsy would increase demand for narcolepsy products. The end-use category for hospitals is anticipated to contribute the most to the overall market because of the rise in narcolepsy patients seeking treatment at these facilities.

The market in North America is expected to continue dominating the market and derive benefits from factors such as higher healthcare expenditure, presence of strong players, and favourable reimbursement policy structure. The high prevalence rate of narcolepsy in the United States and Canada are further expected to help attract significant revenues for this region. A strong clinical pipeline also helps to sustain the local narcolepsy medication industry. A sizable portion of the population still has at least one sleep-related condition, which is expected to maintain the market's potential for growth higher in North America.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Narcolepsy Drugs Market Competitive Landscape

Narcolepsy Drugs Market Report Snapshots

Want to customize this report?

FAQs

Request Free Customization

Feedback From Our Clients

$5,300

Narcolepsy Drugs Market Competitive Landscape

Narcolepsy Drugs Market Report Snapshots

Want to customize this report?

FAQs

What is the market size of Narcolepsy Drugs Market?

Who are the key vendors in the Narcolepsy Drugs Market?

What is the key driver of Narcolepsy Drugs Market?

What is the key market trend for Narcolepsy Drugs Market?

Which region accounted for the largest share in Narcolepsy Drugs Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300